05 February 2014

Targeting Tyrosine Kinase Pathway: Where do we stand?

All credit to Majdy Idrees, FPVRI, Head of SAPH, Riyadh Military Hospital, Vancouver | Canada

Presented at 7th Annual Joint Pulmonary Hypertension Assembly, SAPH2014, May 1-3 2014, Muscat, Oman


Additional key-words:  imatinib,tyrosine kinase inhibitor,vasoreactivity,IMPRES,cancer

Science that starts with a hello.

Through global collaboration, we make today's work, tomorrow's possibility.

Join the PVRI